sabril
Lundbeck sales slide as generic competition bites
November 6, 2014Sales and Marketing Ebixa, Lundbeck, Q3, Xenazine, generic, onfi, sabril
Lundbeck’s sales fell dramatically in the third quarter of 2014 as it struggles with expiring patents, although several of its …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
